Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan

被引:0
|
作者
Shigeru Honda
Yasuo Yanagi
Hideki Koizumi
Yirong Chen
Satoru Tanaka
Manami Arimoto
Kota Imai
机构
[1] Osaka City University Graduate School of Medicine,Department of Ophthalmology and Visual Sciences
[2] Asahikawa Medical University,Department of Ophthalmology
[3] University of the Ryukyus,Department of Ophthalmology, Graduate School of Medicine
[4] Kantar Health,undefined
[5] Novartis Pharma K.K.,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009–2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.
引用
收藏
相关论文
共 50 条
  • [1] Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan
    Honda, Shigeru
    Yanagi, Yasuo
    Koizumi, Hideki
    Chen, Yirong
    Tanaka, Satoru
    Arimoto, Manami
    Imai, Kota
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [2] Innovative therapies for neovascular age-related macular degeneration
    Al-Khersan, Hasenin
    Hussain, Rehan M.
    Ciulla, Thomas A.
    Dugel, Pravin U.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1879 - 1891
  • [3] Gene Therapies for Neovascular Age-Related Macular Degeneration
    Pechan, Peter
    Wadsworth, Samuel
    Scaria, Abraham
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (07):
  • [4] Preferred therapies for neovascular age-related macular degeneration
    Chiang, Allen
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 199 - 204
  • [5] Preferred therapies for neovascular age-related macular degeneration
    Lally, David R.
    Gerstenblith, Adam T.
    Regillo, Carl D.
    CURRENT OPINION IN OPHTHALMOLOGY, 2012, 23 (03) : 182 - 188
  • [6] Neovascular age-related macular degeneration - Potential therapies
    Chappelow, Aimee V.
    Kaiser, Peter K.
    DRUGS, 2008, 68 (08) : 1029 - 1036
  • [7] The economic and humanistic burden of patients in receipt of current available therapies for neovascular age-related macular degeneration
    Jaffe, Dena H.
    Chan, Wing
    Bezlyak, Vladimir
    Skelly, Adrian
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (11) : 1125 - 1132
  • [8] Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
    Samanta, Anindya
    Aziz, Aamir A.
    Jhingan, Mahima
    Singh, Sumit Randhir
    Khanani, Arshad
    Chhablani, Jay
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2020, 9 (03): : 250 - 259
  • [9] Review of Combination Therapies for Neovascular Age-Related Macular Degeneration
    Couch, Steven M.
    Bakri, Sophie J.
    SEMINARS IN OPHTHALMOLOGY, 2011, 26 (03) : 114 - 120
  • [10] Treatment of neovascular age-related macular degeneration: Current therapies
    Augustin, Albert J.
    Scholl, Stefan
    Kirchhof, Janna
    CLINICAL OPHTHALMOLOGY, 2009, 3 : 175 - 182